Managing the Risk of Nitrosamine Impurities

Publication
Article
Pharmaceutical TechnologyPharmaceutical Technology-03-15-2021
Volume 2021 eBook
Issue 1
Pages: 28–35

Collaborative industry efforts have shed light on ways industry standards can help pharma companies better understand the risks nitrosamines pose to the supply chain.

IQ Consortium working groups have engaged in ongoing efforts to evaluate risk models and guidance documents to help increase pharma industry knowledge about these impurities.

Read this article in Pharmaceutical Technology's Regulatory Sourcebook March 2021 eBook.

Article Details

Pharmaceutical Technology
eBook: Regulatory Sourcebook,
March 2021
Pages: 28–35

Citation

When referring to this article, please cite it as T. Curran and J.P. Bercu, "Managing the Risk of Nitrosamine Impurities," Pharmaceutical Technology Regulatory Sourcebook eBook (March 2021).

Articles in this issue
PAULISTA - STOCK.ADOBE.COM
It Takes a Bio/Pharma Village
PAULISTA - STOCK.ADOBE.COM
Enabling the Virtual Human Through Physiologically-based Pharmacokinetic Modeling
PAULISTA - STOCK.ADOBE.COM
Managing the Risk of Nitrosamine Impurities
Image of scientist with test tube and DNA helix
Overcoming Challenges to Biopharmaceutical Development and Manufacture with Science- and Risk-Based Strategies
Extrapolating Data from Adult Clinical Trials to Advance Pediatric Drug Development
Extrapolating Data from Adult Clinical Trials to Advance Pediatric Drug Development
PAULISTA - STOCK.ADOBE.COM
Collaborative Efforts Address Key Data Integrity Challenges
Can FDA Reinvent Inspections
Can FDA Reinvent Inspections
THODONAL - STOCK.ADOBE.COM
FDA 2021 Guidance Agenda Sees Focus on Generics
A Real-World Approach to Evaluating Cleanroom Garments
A Real-World Approach to Evaluating Cleanroom Garments
Resources, Guidelines, and Guidance Documents Directory
Resources, Guidelines, and Guidance Documents Directory
Regulatory and Standard Setting Organizations Directory
Regulatory and Standard Setting Organizations Directory
Recent Videos
Behind the Headlines episode 6
Related Content
Communication between the manufacturing plant and retail stores. | Image Credit: © Cagkan - © Cagkan - stock.adobe.com

Three New European Facilities Established by BioPharmaSpec for R&D

Feliza Mirasol
November 21st 2024
Article

Located in German, Italy, and Lithuania, the new European facilities will specialize in drug discovery and R&D services.

Drug Solutions Podcast: Growth and Advancements in Fill/Finish

Drug Solutions Podcast: Growth and Advancements in Fill/Finish

Felicity Thomas
June 25th 2024
Podcast

In this episode, Hanns-Christian Mahler from ten23 Health chats about the advances in fill/finish.

Science laboratory test tubes, laboratory equipment | Image Credit: © BillionPhotos.com - © BillionPhotos.com - stock.adobe.com

EMA’s CHMP Gives Positive Opinion for Use of Lecanemab in Early Alzheimer’s Disease

Felicity Thomas
November 16th 2024
Article

CHMP has granted Eisai Europe and Biogen a positive opinion for the use of their monoclonal antibody therapy in treating early Alzheimer’s disease.

Drug Solutions Podcast: All About Data: Looking at the EHDS in More Detail

Drug Solutions Podcast: All About Data: Looking at the EHDS in More Detail

Felicity Thomas
May 28th 2024
Podcast

In this episode, Alexander Natz from EUCOPE chats about the European Health Data Space.

Science laboratory test tubes, laboratory equipment | Image Credit: © BillionPhotos.com - © BillionPhotos.com - stock.adobe.com

J&J’s Balversa Gains MHRA Marketing Authorization as Monotherapy for Bladder Cancer

Feliza Mirasol
November 8th 2024
Article

Balversa (erdafitinib) marks the first and only bladder cancer therapy to target FGFR3 alterations, with a demonstrated increase in overall survival from 7.8 months to 12.1 months.

Text sign showing Industry News. Business photo text delivering news to the general public or a target public | Image Credit: © Artur - © Artur - stock.adobe.com

UK Medicines Manufacturing Skills Centre Stresses Skill Development after Budget Announcement

Susan Haigney
November 8th 2024
Article

A £520 million investment for manufacturing capacity was announced by Chancellor of the Exchequer, Rachel Reeves, but academic and industry leaders stress the money should be used to train personnel.